Accepted on 30 May 2021
Submitted on 27 Oct 2020
Sarcopenia, the age-related muscle decline is a significant health problem in the elderly. The loss of muscle mass and strength start in the fourth decade of life and progresses at 3–8% per decade [1]. The prevalence of sarcopenia is 5–13% between 60 and 70 years of age and further increases with advancing age, reaching up to 50% in octogenarians [2]. It is also frequently associated with adverse events such as fall, osteoporosis, dependent lifestyle, and mortality.
While sarcopenia is a physiological process, several geriatric comorbidities can accelerate its progression. Among them, chronic heart failure (CHF) is a well-recognized co-morbidity in the elderly. CHF is caused by cardiac contractile or diastolic dysfunction with reduced cardiac output and progressive deterioration of the cardiac contractility. Sarcopenia is frequently associated with CHF, which may further deteriorate cardiac and skeletal muscle dysfunction [3]. The prevalence of sarcopenia is ≈20% higher in the elderly with CHF than healthy individuals [4]. Further, sarcopenia in CHF patients has an early onset, irrespective of cardiac output and requires timely diagnosis and monitoring for proper interventions [3]. However, the search for an effective biomarker to characterize sarcopenia in CHF patients remains elusive.
Micro RNAs (miRs) are small non-coding RNAs, 21–23 nucleotides in length and regulate gene transcription by repressing translation and/or degrading mRNAs [5]. Several reports recognize an essential role of miRs in skeletal muscle health and disease, as aberrant expression of miRs is associated with multiple skeletal muscle diseases including sarcopenia [5, 6]. miRs derived from skeletal muscle and other tissues are easily detectable in circulation, indicating their diagnostic potential in sarcopenia. Several studies indicate an altered expression of both the muscle-specific and non-muscle specific miRs in the circulation in the elderly [5, 6]. Additionally, the patients with CHF also show significant alterations in the plasma miRs profile [7]. Among the several circulating miRs levels perturbed in sarcopenia and/or CHF, miR-21, miR-181a, miR-133a, miR-424-5p, mir-434-3P and miR-455-3P have emerged as potential candidates for diagnosing and/or monitoring muscle health [8, 9]. However, their association with sarcopenia indexes in healthy aging and in patients with CHF as well as their diagnostic potential in CHF are not well characterized. Further, several factors including different detection methods (RT-PCR, microarray, high throughput sequencing), variability in patients’ clinical conditions including age and sex, and limited sample size may account for the discrepancy in the literature which may reduce the diagnostic potential of the miRs. Additionally, systemic oxidative stress and chronic inflammation can also affect generalized health and circulating miRs levels but their correlation with selected miRs in sarcopenia is not known. In this study, we asked whether the circulating levels of selected miRs correlate with the indexes of sarcopenia during healthy aging and in patients with CHF.
We recruited 181 ambulatory male participants as healthy controls (N = 92) and patients with CHF (N = 89) after obtaining ethical approvals at the University of Health Sciences, Lahore (approval #UHS/ERB/22587/2016), teaching hospital of Gomal Medical College, Dera Ismail Khan (approval #GMC/157/2016) and cardiac rehabilitation center, Hayatabad Medical Complex, Peshawar, (approval #HMC/253/2017), Pakistan. The regional research ethical committees at these university hospitals approved this study. All participants provided written informed consent. The inclusion criteria for the CHF patients were a clinical diagnosis of heart failure with left ventricular ejection fraction (EF) ≤40% as measured by echocardiography. Based on EF, CHF patients were divided into moderate (EF = 26.4–32.9%) and mild (33–39.9%) CHF. Among the CHF patients, 43 patients (mild CHF = 29, moderate CHF = 14) were on anti-platelets therapy, while seven patients (mild CHF = 6, moderate CHF = 1) were on anti-coagulant therapy. Patients with heart transplantation, major surgeries, unstable angina, myocardial infarction, and stroke as well as with prolonged bed rest within eight weeks of the visit to the clinics were excluded. Hence, our study protocol is consistent with a previous study used to characterize muscle wasting in patients with CHF [10]. Data was collected from structural interviews, clinical examinations, laboratory investigations and measurements of physical parameters. This study was conducted in accordance with the declaration of Helsinki [11].
Hand-grip strength was measured by a digital handgrip dynamometer (CAMRY, South El Monte, CA, USA) as described before [12, 13]. The participants were asked to sit down and squeeze the dynamometer with maximal strength in a smooth manner. Three attempts were performed with each hand with 60-seconds rest between each attempt and the highest value was recorded for the analysis. Appendicular skeletal muscle mass (ASM) and fat mass were calculated with the bioelectrical impedance analysis scale (RENPHO, Dubai, UAE). ASM was divided by height square to get the appendicular skeletal muscle mass index (ASMI), as described previously [14].
The physical performance was assessed by the short physical performance battery (SPPB) score. This battery is composed of three timed tests: 4-m walking speed, balance, and chair-stand tests. Timed results from each test were rescored from zero (worst performers) to four (best performers). The sum of the results from the three categorized tests (ranging from 0 to 12) was used for the present analyses, as described elsewhere [15].
The walking speed was evaluated by measuring the participant’s usual gait-speed (in m/s) over a 4-m course (4-meter walk test; 4MWT). Based on the sample population quartiles, the following cut-points were used to categories the gait speed: ≤0.38 m/s, a score of 1; 0.39–0.57m/s, a score of 2; 0.58–0.76m/s, a score of 3; ≥ 0.77m/s, a score of 4.
To assess the chair-stand test, the participants were asked to stand up from a chair with their arms folded across the chest five times in a row as quickly as possible. The time needed to complete the task was recorded. The quartiles for the length of the time required for this measure was used for scoring as follows: ≥17.0s, a score of 1; 14.1–16.9s, a score of 2; 11.9–14.0s, a score of 3; and ≤ 11.8s, a score of 4.
To assess the balance test, the participants were asked to perform three increasingly challenging standing- positions: side-by-side position, semi-tandem position, and tandem position. Participants were asked to hold each position for 10s. Participants were scored as 1 if they were able to hold a side-by-side standing position for 10s, but were unable to hold a semi-tandem position for 10s; a score of 2 if they were able to hold a semi-tandem position for 10s, but were unable to hold a tandem position for more than 2s; a score of 3 if they were able to stand in tandem position for 3–9s; and a score of 4 if they were able to hold the tandem position for 10s.
We used ELISA to measure 8-isoprostanes (Cayman Chemical, Ann Arbor, MI, USA) and CRP (R&D Systems, Minneapolis, MN, USA) levels and biochemical assays to measure creatine kinase levels, as described previously [16].
Total RNA was extracted from the blood using TRI reagent and the cDNA was prepared from 1 mg of the total RNA using iScriptTM cDNA Synthesis kit (Bio-Rad, Hercules, CA, USA) as described previously [17]. Two point five ng of cDNA samples were amplified using specific primers along with fast SYBR green master mix (Applied Biosystems, Grand Island, NY, USA). The data were analyzed using the ΔΔCt method [18].
Bulge-LoopTM miRNA qPCR Primer Sets (RiboBio) were used to detect selected miRs expressions by qRT-PCRs with iTaq TM Universal SYBR Green Supermix (BIO-RAD) as described elsewhere [8]. Reverse transcription of the miRs into cDNA was done with the TaqMan microRNA reverse transcription kit (Thermo Fisher, Dubai, UAE) and TaqMan microRNA assays specific for selected miRs (Applied Biosystems, Thermo Fisher, Dubai, UAE) according to the manufacturer’s recommendations. Owing to several PCR sessions to analyze a high number of samples, we created a reference sample by pooling a fraction of all control and CHF samples. This reference sample was run in each PCR session to minimize the technical variability in our samples. All qRT-PCR reactions were performed in triplicate, and the signal was collected at the end of every cycle. All miRs expressions were calibrated against spike-in cel-miR-39, which lacks sequence homology to human miRs.
Anthropometric measurements of the participants were presented using mean and standard deviation as data met the assumption for normality. Analysis of variance was used to compare groups and Pearson correlation was employed to determine the strength of the relationship between miRs levels and physical characteristics. ASM, ASMI, plasma CRP, 8-isoprostanes and CK levels were adjusted for anti-platelets therapy and daily step count, using multiple regression model. A two-sample t-test for percent was used to compare SPPB scores between the groups. Receiver operating characteristic curves were used to evaluate the sensitivity and specificity of each miR. Outliers were identified and omitted through statistical analysis. A p-value < 0.05 was statistically significant.
The basic characteristics of the study population are summarized in Table 1. Overall, the CHF patients had lower BMI, body fats and ASMI, HGS, walking speed and daily steps count (all p < 0.05). These patients also performed poorly on SPPB scores than the healthy controls (all p < 0.05). Moreover, CHF was associated with lower plasma HDL-C levels and higher total cholesterol, LDL-C, triglycerides, 8-isoprostanes and CRP (all p < 0.05) (Table 1).
Table 1
Age, body composition, physical parameters, and plasma profile of healthy controls (n = 92) and patients with CHF (n = 89). Based on EF, CHF patients were divided into moderate (EF = 26.4–32.9%) and mild (33-39.9%) CHF. The numbers in parenthesis indicate the percentage of total participants for that category. Values are expressed as mean ± SD; *p < 0.05 vs. healthy controls, #p < 0.05 vs. moderate CHF. (BMI; body mass index, ASM; appendicular skeletal mass, HGS; handgrip strength, HDL; high-density lipoproteins, HbA1c; glycosylated hemoglobin, CRP; C – reactive protein).
| Healthy controls | CHF | |||
|---|---|---|---|---|
| n = 92 | All (n = 89) | Mild (n = 63) | Moderate (n =26) | |
| Age at baseline (years) | 67.7 ± 5.3 | 64.4 ± 6.5 | 63.5 ± 6.1 | 66.5 ± 7.1 |
| Body composition | ||||
| BMI (Kg/m2) | 24.8 ± 2.8 | 22.2 ± 2.9* | 22.5 ± 3.1* | 21.5 ± 2.6* |
| ASM (Kg) | 22.4 ± 3.1 | 21.1 ± 2.3 | 21.5 ± 2.6 | 20 ± 2.1* |
| Percent fat | 29.8 ± 2.7 | 25.4 ± 3.1* | 25.5 ± 3.2* | 25.1 ± 3.3* |
| ASMI (Kg/m2) | 6.8 ± 1.8 | 6.2 ± 1.4* | 6.3 ± 1.44 | 6.1 ± 1.31 |
| Physical capacity | ||||
| HGS (Kg) | 23.5 ± 3.2 | 18.6 ± 3.3* | 19.5 ± 3* | 16.4 ± 3.6*# |
| HGS/ASM | 1.05 ± 0.21 | 0.88 ± 0.18* | 0.90 ± 0.15* | 0.81 ± 0.21*# |
| 4-meter walking Speed (m/s) | 1.18 ± 0.17 | 0.97 ± 0.13* | 1.01 ± 0.11* | 0.87 ± 0.19* |
| Daily steps count | 5,211 ± 1113 | 3,427 ± 838* | 3,708 ± 813* | 2,746 ± 928* |
| SPPB score | ||||
| 12 | 44 (47.8) | 4 (4.4)* | 4 (6.3)* | 0 |
| 11 | 18 (19.5) | 8 (8.9)* | 6 (9.5)* | 2 (7.7) |
| 10 | 15 (16.3) | 22 (24.7)* | 17 (27) | 5 (19.2) |
| 9 | 7 (7.6) | 33 (37.1)* | 24 (38)* | 9 (34.6)* |
| 8 | 5 (5.4) | 17 (19.1)* | 11 (17.5)* | 6 (23.1)* |
| 7 | 3 (3.2) | 4 (4.5) | 1 (1.6) | 3 (11.5) |
| 6 | 0 | 1 (1.1) | 0 | 1 (3.8) |
| Plasma profile | ||||
| Total Cholesterol | 187.4 ± 25.4 | 236.3 ± 39.8* | 232.4 ± 40.5* | 246.5 ± 37.9* |
| HDL-C (mg/dl) | 40.2 ± 2.8 | 37.1 ± 2.7* | 37.4 ± 2.8 | 36.4 ± 2.2* |
| LDL-C (mg/dl) | 97.8 ± 14.9 | 149.8 ± 29.2* | 146.3 ± 24.9* | 154.4 ± 33.5* |
| Triglycerides (mg/dl) | 144.3 ± 26.3 | 197.6 ± 39.3* | 189.4 ± 35.5* | 216.5 ± 42.3* |
| HbA1c (%) | 5.81 ± 0.11 | 5.93 ± 0.17 | 5.89 ± 0.15 | 6.04 ± 0.19 |
| 8-isoprostanes (pg/ml) | 51.6 ± 9.7 | 106.9 ± 28.5* | 102.4 ± 26.2* | 116.7 ± 32.6*# |
| CRP (mg/dl) | 0.15 ± 0.03 | 0.32 ± 0.08* | 0.31 ± 0.07* | 0.34 ± 0.07* |
| Creatine kinase (IU/L) | 182.3 ± 19.7 | 291.4 ± 38.7 | 281.7 ± 34.6 | 315.3 ± 37.4* |
We next measured the levels of selected circulating miRs and mRNA markers of inflammation and oxidative stress in the healthy controls and CHF patients. Among the miRs, miR-21 levels were upregulated while miR-181a, miR-133a, miR-434-3p and miR-455-3p levels were downregulated in the patients with CHF (all p < 0.05), when compared to control group (Figure 1A).
Relative expressions of the plasma miRs (A) and the markers of inflammation and oxidative stress (B) in the healthy controls (n = 92) and the patients with CHF (n = 89). Values are expressed as mean ± SEM, *p < 0.05 vs. the healthy controls. (Interleukin-10, IL-10; Transforming growth factor-beta 1, TGF-b1; c-c motif chemokine receptor 5, CCR5; c-x-c motif chemokine ligand 8, CXCL-8; Interleukin-6, IL-6; c-x-c motif chemokine ligand 2, CXCL2; adrenomedullin, ADM; superoxide dismutase-1, SOD1; glutathione synthetase, glutathione peroxidase-1 GPX1).
Since these miRs also regulate inflammation and cellular redox environment, we next measured the plasma mRNA markers of inflammation and oxidative stress. We found higher plasma levels of pro-inflammatory cytokines IL-10, TGF-b1 and ADM, and antioxidant enzymes SOD1, catalase, GSS and GPX1 in the patients with CHF (all p < 0.05), when compared to controls (Figure 1B). We further confirmed the increased inflammation and oxidative stress in CHF patients by reporting elevated plasma levels of CRP (107%, p < 0.05) and 8-isoprostanes (113%, p < 0.05) in CHF patients than healthy controls (Table 1).
European working group on sarcopenia in older people characterizes sarcopenia with low muscle strength and mass, and low gait speed [19]. We used HGS, ASM, ASMI and 4MWT as the indexes for the detection of sarcopenia. All six miRs showed statistically significant correlations with HGS in healthy controls and patients with CHF (Figure 2) (all p < 0.05).
Linear regression analysis of the relationships of plasma miRs with hand-grip strength (HGS) in healthy controls (n = 92) and patients with the CHF (n = 89).
Among the individual miRs, miR-133a showed the strongest correlation with HGS in controls (r2 = 0.203, p < 0.001) and CHF group (r2 = 0.167, p < 0.001). We also found significant correlations of other miRs with ASM in both study cohorts except miR-21 and miR 434-3p in healthy controls and miR-181a in CHF group (all p < 0.05). However, when ASM was adjusted for height square (ASMI), a significant correlation was only found with miR-434-3p (in healthy controls), miR-133a (in CHF group) and miR-455-3p (in healthy controls and CHF groups) (all p < 0.05). On the other hand, 4MWS showed significant correlation with miR-133a and miR-455-3p (healthy controls) and all the miRs except miR-455-3p (in patients with CHF) (all p < 0.05) (Table 2).
Table 2
Correlations coefficients (r2) of circulating mi-RNAs with absolute and adjusted (for anti-coagulant therapy and daily step count) HGS, ASM, ASMI and 4MWS in healthy controls (n = 92) and participants with CHF (n = 89), * p < 0.05.
| MiR-21 | MiR-181a | miR-133a | MiR-424-5p | MiR-434-3p | MiR-455-3p | |
|---|---|---|---|---|---|---|
| HGS | ||||||
| Healthy | 0.184* | 0.129* | 0.203* | 0.098* | 0.112* | 0.124* |
| CHF | 0.126* | 0.122* | 0.167* | 0.157* | 0.115* | 0.139* |
| ASM | ||||||
| Healthy | 0.126 | 0.204* | 0.136* | 0.116* | 0.098 | 0.321* |
| CHF | 0.246* | 0.171 | 0.15* | 0.112 | 0.204* | 0.24* |
| ASMI | ||||||
| Healthy | 0.086 | 0.059 | 0.095 | 0.058 | 0.118* | 0.128* |
| CHF | 0.034 | 0.018 | 0.273* | 0.104* | 0.081 | 0.094* |
| 4MWS | ||||||
| Healthy | 0.065 | 0.049 | 0.083* | 0.067 | 0.096 | 0.113* |
| CHF | 0.089 | 0.177* | 0.095* | 0.137* | 0.128* | 0.098 |
| Adjusted HGS | ||||||
| Healthy | 0.131* | 0.103* | 0.184* | 0.075* | 0.063 | 0.103* |
| CHF | 0.109* | 0.128* | 0.181* | 0.139* | 0.078 | 0.164* |
| Adjusted ASM | ||||||
| Healthy | 0.107 | 0.225* | 0.124* | 0.096 | 0.109* | 0.285* |
| CHF | 0.155* | 0.104 | 0.157* | 0.135* | 0.188* | 0.256* |
| Adjusted ASMI | ||||||
| Healthy | 0.075 | 0.068 | 0.064 | 0.086 | 0.129* | 0.155* |
| CHF | 0.046 | 0.024 | 0.183* | 0.169* | 0.108* | 0.109* |
| Adjusted 4MWS | ||||||
| Healthy | 0.098* | 0.055 | 0.074 | 0.075 | 0.122* | 0.205* |
| CHF | 0.084 | 0.205* | 0.108* | 0.103* | 0.187* | 0.129* |
We next tested the diagnostic potentials of circulating miRs in CHF patients with sarcopenia, using receiver-operative characteristic (ROC) curves (Figure 3). While all miRs displayed significant values, we found that the miR-424-5p exhibited the highest area under the curve (AUC = 0.85), followed by miR-21 and miR-181a (both AUC = 0.80). On the other hand, miR-424-5p displayed the lowest but still significant value (AUC = 0.61) (Figure 3).
ROC curve illustrating sensitivity and specificity of the plasma miRs in discriminating healthy controls (n = 92) from the patients with CHF (n = 89).
Given the importance of the selected miRs in the regulation of inflammation, oxidative stress, and muscle health, we next determined the correlations of plasma 8-isoprostanes, CRP and CK levels with circulating miRs expressions. Plasma 8-isoprostanes levels, a marker of oxidative stress showed significant correlation with miR-455-3p (healthy controls), miR-181a (CHF group) and miR-424-5p (in both groups) (all p < 0.05) (Table 3) [20]. On the other hand, plasma GRP level, a marker of generalized inflammation showed significant correlation with miR-455-3p (healthy controls), miR-21, miR-424-5p, miR-434-3p (CHF group), miR-133a and miR-455-3p (in both groups) (all p < 0.05). Plasma CK levels are increased in muscle injury and were correlated with miR-181a (healthy controls), miR-21 (CHF group), miR-133a, miR-424-5p, miR434-3p and miR-455-3p (in both groups) (all p < 0.05) (Table 3).
Table 3
Correlations coefficients (r2) of circulating mi-RNAs with absolute and adjusted (for anti-coagulant therapy and daily stem count) plasma 8-isoprostanes and CRP levels in healthy controls (n = 92) and participants with CHF (n = 89), * p < 0.05.
| MiR-21 | MiR-181a | miR-133a | MiR-424-5p | MiR-434-3p | MiR-455-3p | |
|---|---|---|---|---|---|---|
| 8-isoprostanes | ||||||
| Healthy | 0.094 | 0.105 | 0.095 | 0.239* | 0.053 | 0.079* |
| CHF | 0.079 | 0.185* | 0.119 | 0.179* | 0.076 | 0.068 |
| CRP | ||||||
| Healthy | 0.134 | 0.046 | 0.149* | 0.028 | 0.071 | 0.139* |
| CHF | 0.169* | 0.108* | 0.253* | 0.131* | 0.105* | 0.261* |
| Plasma CK | ||||||
| Healthy | 0.085 | 0.103* | 0.187* | 0.379* | 0.158* | 0.141* |
| CHF | 0.129* | 0.094 | 0.353* | 0.413* | 0.224* | 0.178* |
| Adjusted 8-isoprostanes | ||||||
| Healthy | 0.081 | 0.129* | 0.071 | 0.204* | 0.059 | 0.097* |
| CHF | 0.098 | 0.151* | 0.089 | 0.191* | 0.071 | 0.074 |
| Adjusted CRP | ||||||
| Healthy | 0.155* | 0.053 | 0.163* | 0.036 | 0.084 | 0.128* |
| CHF | 0.188* | 0.094* | 0.204* | 0.152* | 0.118* | 0.218* |
| Adjusted Plasma CK | ||||||
| Healthy | 0.104 | 0.129* | 0.166* | 0.398* | 0.144* | 0.166* |
| CHF | 0.144* | 0.104 | 0.308* | 0.367* | 0.219* | 0.152* |
The following major findings emerge from our study: 1) Patients with CHF had lower plasma miR-21 and higher plasma miR-181a, miR-133a, miR-434-5-p and miR-455-3p levels than the healthy controls. 2) Among the plasma miRs, miR-133a showed the strongest correlations with HGS, while miR-133a, miR-434-3p and miR-455-3p showed the strongest correlation with ASMI. 3) miR-434-3p shows the highest area under the curve in the testing for sensitivity and specificity for CHF.
Sarcopenia is a senile syndrome with very complex pathogenesis. Several diseases can induce muscle atrophy and weakness independent of aging, indicating the susceptibility of skeletal muscle to systemic morbidities. Patients with CHF have a higher prevalence of sarcopenia than the age-matched elderly without CHF [10]. Further, the rate of muscle decline is faster in these patients, leading to a further reduction in physical capacity and cardiac function [21, 22]. Circulating miRs hold a great potential as biomarkers of muscle decline in CHF. However, several limitations reduce the diagnostic potentials of miRs in sarcopenia. Indeed, inaccurate normalization methods and smaller sample pools can partly account for the discrepancy in the literature. Further, the variability in clinical conditions of CHF patients can also hamper the reproducibility of the data. We analyzed more than 180 subjects in this study, which is a considerable sample size to draw stronger conclusions. Stringent normalization methods and acceptance criteria were used to further enhance the confidence in our data.
Several of the miRs showed significant correlations, albeit biologically weak, with the clinical parameters of sarcopenia, supporting the hypothesis that the altered plasma expressions of these miRs are specifically related to muscle damage. Among the various miRs investigated here, miR-133a is primarily produced by skeletal muscle and has a role in muscle differentiation and proliferation [23]. Aging is associated with an upregulation of miR-133a expression in skeletal muscle [5]. However, it is not known whether the plasma miR-133a levels are due to active secretion by skeletal muscles or passive release from the damaged myofibers. We found a strong association between plasma miR-133a and CK levels, which indicates that the muscle damage is at least partly contributing to plasma miR-133a levels. Indeed, the CHF results in skeletal muscle damage and necrosis [24], which can facilitate passive release of miR-133a into circulation. Other miRs investigated here are released by multiple tissues including nervous tissues, testes, epididymis and spleen (https://ccb-web.cs.uni-saarland.de/tissueatlas/). Thus, the perturbations in plasma levels of these miRs may represent the generalized clinical condition of the CHF patients rather than muscle-specific disorders. This is not surprising, considering the multi-system effects of CHF [25].
We found considerable discordance between the ROC analysis and the predictive power of miRs in diagnosing sarcopenia. For example, miR-434-3p had the highest AUC on the ROC curve but performed relatively poorly in diagnosing loss of muscle mass, strength, and physical capacity. miR-434-3p is importantly expressed in both the cardiac and skeletal muscle and has a pathological role in both tissues [6, 26]. For example, the expression of miR-434-3p is increased in the failing heart in heart diseases [26]. Plasma miR-434-3p levels also reflect muscle atrophy during aging [6]. Thus, it is possible that the different contributions of skeletal and cardiac muscles to the circulating miR-434-3p levels account for different discriminating power in assessing cardiac and skeletal muscle health.
We did not perform a functional analysis to investigate the target genes of selected miRs. However, to gain insight into the possible mechanisms by which these miRs regulate muscle health, we used Target Scan (http://www.targetsca.org/), an online database for predicting miR targets. We found between 400 to 1900 targets for miR-121, miR-424-5p, miR-133a, miR-455-3p and miR-181a, while miR 434-3p was not in the Target Scan database. We next used the Kyoto encyclopedia of genes and genomes pathway analysis (http://www.kegg.jp/kegg/pathway.html) with a cut-off criteria of a target gene number > 2 and p < 0.05. We found the involvement of pathways associated with skeletal muscle calcium signaling, protein synthesis, MAPK signaling, unfolded protein response, ERK and FOXO signaling. We also found a role of miR-434-3p in regulating age-related apoptosis in the skeletal muscle [27].
The expressions of selected miRs in the erythrocytes is minimal or non-existence, which largely rules out potential distorting effects of hemolysis [28]. Additionally, large sample size and stringent normalization and acceptance criteria are the strengths of this study. Nevertheless, some limitations must be acknowledged. The study includes men only so we cannot dissect these effects in a gender-specific manner. This is important since a gender-bias is recognized in the expressions of some miRs including miR-133 [29, 30]. We did not measure the quadriceps strength, which is also used apart from HGS as a sarcopenia index [31]. The selective survival of the CHF patients before inclusion in this study is worth consideration. The pathophysiological mechanism(s) by which the selected miRs contribute to sarcopenia phenotype in CHF remains elusive. We also did not characterize the relative contributions of skeletal and cardiac muscles and other tissues to the circulating miRs levels. We also do not know if the detected circulating miRs are primarily released via active mechanisms or due to tissue damage.
Taken together, we show that the plasma miR-133a, miR-434-3p and miR-455-3p can potentially act as novel biomarkers of skeletal muscle health and physical capacity in CHF. Their plasma levels can also provide information on functional compromise and risk stratification in sarcopenia with CHF. Additional studies with a more mechanistic approach are required to characterize the functions of these miRs in sarcopenia.
Raw data from the patient cohorts cannot be shared due to the intellectual property rights but are available from the corresponding author on reasonable request.
The regional research ethical committees at the hospitals of the University of Health Sciences, Lahore, and teaching hospital of Gomal Medical College, Dera Ismail Khan and cardiac rehabilitation center, Hayatabad Medical Complex, Peshawar, Pakistan approved this study. All participants provided written informed consent.
This work was supported by grants from the University of Sharjah to Rizwan Qaisar (Competitive grant # 1901090157, Target grant # 1901090168). We are thankful to Waleed Yousaf, Faisal Nadeem & Ahmad Hassan Nadeem for helping with data analysis.
The authors have no competing interests to declare.
Conceptualization: R.Q., A.K., Data curation: T.M., I.S, J.K., Formal analysis: R.Q., Funding acquisition: R.Q., A.K., Investigation: T.M., I.S, J.K., R.Q., Methodology: R.Q., Project administration: R.Q., A.K., T.M., Resources: R.Q., A.K., Supervision: R.Q. I.S., T.M., J.K., Validation: R.Q., A.K., Writing – original draft: R.Q., Writing – review & editing: R.Q., A.K.
von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: Facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010; 1(2): 129–33. DOI: https://doi.org/10.1007/s13539-010-0014-2
Morley JE. Sarcopenia: Diagnosis and treatment. J Nutr Health Aging. 2008; 12(7): 452–6. Epub 11 July 2008. DOI: https://doi.org/10.1007/BF02982705
Collamati A, Marzetti E, Calvani R, et al. Sarcopenia in heart failure: Mechanisms and therapeutic strategies. J Geriatr Cardiol. 2016; 13(7): 615–24. Epub 09 September 2016.
Fulster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: Results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J. 2013; 34(7): 512–9. Epub 28 November 2012. DOI: https://doi.org/10.1093/eurheartj/ehs381
Kim JY, Park YK, Lee KP, et al. Genome-wide profiling of the microRNA-mRNA regulatory network in skeletal muscle with aging. Aging (Albany NY). 2014; 6(7): 524–44. DOI: https://doi.org/10.18632/aging.100677
Jung HJ, Lee KP, Milholland B, et al. Comprehensive miRNA Profiling of Skeletal Muscle and Serum in Induced and Normal Mouse Muscle Atrophy During Aging. J Gerontol A Biol Sci Med Sci. 2017; 72(11): 1483–91. DOI: https://doi.org/10.1093/gerona/glx025
Huang YM, Li WW, Wu J, Han M, Li BH. The diagnostic value of circulating microRNAs in heart failure. Exp Ther Med. 2019; 17(3): 1985–2003. Epub 21 February 2019. DOI: https://doi.org/10.3892/etm.2019.7177
He N, Zhang YL, Zhang Y, et al. Circulating MicroRNAs in Plasma Decrease in Response to Sarcopenia in the Elderly. Front Genet. 2020; 11: 167. DOI: https://doi.org/10.3389/fgene.2020.00167
Yanai K, Kaneko S, Ishii H, et al. MicroRNAs in Sarcopenia: A Systematic Review. Front Med (Lausanne). 2020; 7: 180. Epub 18 June 2020. DOI: https://doi.org/10.3389/fmed.2020.00180
Steinbeck L, Ebner N, Valentova M, et al. Detection of muscle wasting in patients with chronic heart failure using C-terminal agrin fragment: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail. 2015; 17(12): 1283–93. DOI: https://doi.org/10.1002/ejhf.400
World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013; 310(20): 2191–4. DOI: https://doi.org/10.1001/jama.2013.281053
Qaisar R, Karim A, Muhammad T. Circulating Biomarkers of Handgrip Strength and Lung Function in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020; 15: 311–21. DOI: https://doi.org/10.2147/COPD.S225765
Qaisar R, Karim A, Muhammad T. Plasma CAF22 Levels as a Useful Predictor of Muscle Health in Patients with Chronic Obstructive Pulmonary Disease. Biology (Basel). 2020; 9(7). DOI: https://doi.org/10.3390/biology9070166
Qaisar R, Qayum M, Muhammad T. Reduced sarcoplasmic reticulum Ca(2+) ATPase activity underlies skeletal muscle wasting in asthma. Life Sci. 2021; 273: 119296. Epub 07 March 2021. DOI: https://doi.org/10.1016/j.lfs.2021.119296
Landi F, Russo A, Cesari M, Pahor M, Bernabei R, Onder G. HDL-cholesterol and physical performance: Results from the ageing and longevity study in the sirente geographic area (ilSIRENTE Study). Age Ageing. 2007; 36(5): 514–20. DOI: https://doi.org/10.1093/ageing/afm105
Qaisar R, Karim A, Muhammad T, Shah I. Circulating Biomarkers of Accelerated Sarcopenia in Respiratory Diseases. Biology (Basel). 2020; 9(10). DOI: https://doi.org/10.3390/biology9100322
Qaisar R, Pharaoh G, Bhaskaran S, et al. Restoration of Sarcoplasmic Reticulum Ca(2+) ATPase (SERCA) Activity Prevents Age-Related Muscle Atrophy and Weakness in Mice. Int J Mol Sci. 2020; 22(1). Epub 31 December 2020. DOI: https://doi.org/10.3390/ijms22010037
Alamdari N, Toraldo G, Aversa Z, et al. Loss of muscle strength during sepsis is in part regulated by glucocorticoids and is associated with reduced muscle fiber stiffness. Am J Physiol Regul Integr Comp Physiol. 2012; 303(10): R1090–9. Epub 29 September 2012. DOI: https://doi.org/10.1152/ajpregu.00636.2011
Franzon K, Zethelius B, Cederholm T, Kilander L. The impact of muscle function, muscle mass and sarcopenia on independent ageing in very old Swedish men. BMC Geriatr. 2019; 19(1): 153. DOI: https://doi.org/10.1186/s12877-019-1142-y
Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis. 2003; 14(3): 213–8. DOI: https://doi.org/10.1097/01.mca.0000063504.13456.c3
Yin J, Lu X, Qian Z, Xu W, Zhou X. New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure. Theranostics. 2019; 9(14): 4019–29. DOI: https://doi.org/10.7150/thno.33000
Qaisar R, Karim A, Muhammad T, Shah I, Khan J. Prediction of sarcopenia using a battery of circulating biomarkers. Sci Rep. 2021; 11(1): 8632. Epub 23 April 2021. DOI: https://doi.org/10.1038/s41598-021-87974-6
Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 2006; 38(2): 228–33. Epub 29 December 2005. DOI: https://doi.org/10.1038/ng1725
Song T, Manoharan P, Millay DP, et al. Dilated cardiomyopathy-mediated heart failure induces a unique skeletal muscle myopathy with inflammation. Skelet Muscle. 2019; 9(1): 4. DOI: https://doi.org/10.1186/s13395-019-0189-y
Van Iterson EH, Olson TP. Therapeutic Targets for the Multi-system Pathophysiology of Heart Failure: Exercise Training. Curr Treat Options Cardiovasc Med. 2017; 19(11): 87. DOI: https://doi.org/10.1007/s11936-017-0585-8
Ooi JYY, Bernardo BC, Singla S, Patterson NL, Lin RCY, McMullen JR. Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases. RNA Biol. 2017; 14(5): 500–13. DOI: https://doi.org/10.1080/15476286.2016.1181251
Pardo PS, Hajira A, Boriek AM, Mohamed JS. MicroRNA-434-3p regulates age-related apoptosis through eIF5A1 in the skeletal muscle. Aging (Albany NY). 2017; 9(3): 1012–29. Epub 24 March 2017. DOI: https://doi.org/10.18632/aging.101207
Doss JF, Corcoran DL, Jima DD, Telen MJ, Dave SS, Chi JT. A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes. BMC Genomics. 2015; 16: 952. Epub 18 November 2015. DOI: https://doi.org/10.1186/s12864-015-2156-2
Cui C, Yang W, Shi J, Zhou Y, Yang J, Cui Q. Identification and Analysis of Human Sex-biased MicroRNAs. Genomics Proteomics Bioinformatics. 2018; 16(3): 200–11. Epub 15 July 2018. DOI: https://doi.org/10.1016/j.gpb.2018.03.004
Dai A, Sun H, Fang T, et al. MicroRNA-133b stimulates ovarian estradiol synthesis by targeting Foxl2. FEBS Lett. 2013; 587(15): 2474–82. Epub 03 July 2013. DOI: https://doi.org/10.1016/j.febslet.2013.06.023
Harris-Love MO, Benson K, Leasure E, Adams B, McIntosh V. The Influence of Upper and Lower Extremity Strength on Performance-Based Sarcopenia Assessment Tests. J Funct Morphol Kinesiol. 2018; 3(4). Epub 12 December 2018. DOI: https://doi.org/10.3390/jfmk3040053